Saibal Kar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7921884/publications.pdf

Version: 2024-02-01

81743 40881 14,485 100 39 citations h-index papers

93 g-index 100 100 100 7059 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. New England Journal of Medicine, 2018, 379, 2307-2318.	13.9	2,079
2	Percutaneous Repair or Surgery for Mitral Regurgitation. New England Journal of Medicine, 2011, 364, 1395-1406.	13.9	1,814
3	Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. Journal of the American College of Cardiology, 2014, 64, 1-12.	1.2	1,605
4	Safety of Percutaneous Left Atrial Appendage Closure. Circulation, 2011, 123, 417-424.	1.6	782
5	Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2014, 312, 1988.	3.8	765
6	5-Year Outcomes After Left Atrial Appendage Closure. Journal of the American College of Cardiology, 2017, 70, 2964-2975.	1.2	725
7	Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. Journal of the American College of Cardiology, 2015, 66, 2844-2854.	1.2	658
8	The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 59, 923-929.	1.2	479
9	Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 2614-2623.	1.2	470
10	Percutaneous Mitral Valve Repair for Mitral Regurgitation in High-Risk Patients. Journal of the American College of Cardiology, 2014, 64, 172-181.	1.2	390
11	Outcomes With Transcatheter Mitral Valve Repair in the United States. Journal of the American College of Cardiology, 2017, 70, 2315-2327.	1.2	333
12	Device-Related Thrombus After Left Atrial Appendage Closure. Circulation, 2018, 138, 874-885.	1.6	298
13	Improved Functional Status and Quality of Life in Prohibitive Surgical Risk Patients With Degenerative Mitral Regurgitation After Transcatheter Mitral Valve Repair. Journal of the American College of Cardiology, 2014, 64, 182-192.	1,2	274
14	Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 253-261.	1.2	214
15	Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device. Circulation, 2021, 143, 1754-1762.	1.6	208
16	Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet, The, 2017, 390, 773-780.	6.3	187
17	The Acute Hemodynamic Effects of MitraClip Therapy. Journal of the American College of Cardiology, 2011, 57, 1658-1665.	1.2	176
18	Initial Experience With Commercial Transcatheter Mitral Valve Repair inÂtheÂUnited States. Journal of the American College of Cardiology, 2016, 67, 1129-1140.	1.2	172

#	Article	IF	Citations
19	The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?. European Heart Journal, 2015, 36, 1651-1659.	1.0	168
20	Echocardiographic Outcomes After Transcatheter Leaflet Approximation inÂPatients With Secondary MitralÂRegurgitation. Journal of the American College of Cardiology, 2019, 74, 2969-2979.	1.2	161
21	Institutional Experience With Transcatheter Mitral Valve Repair andÂClinical Outcomes. JACC: Cardiovascular Interventions, 2019, 12, 1342-1352.	1.1	128
22	Transcatheter Valve Repair for PatientsÂWith Mitral Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1369-1378.	1.1	128
23	Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries. Journal of the American College of Cardiology, 2019, 74, 2878-2889.	1.2	124
24	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace, 2017, 19, euw141.	0.7	120
25	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1029-1040.	1.2	113
26	One-Year Outcomes After MitraClip for Functional Mitral Regurgitation. Circulation, 2019, 139, 37-47.	1.6	98
27	Health Status After Transcatheter Mitral-Valve Repair in Heart FailureÂandÂSecondary MitralÂRegurgitation. Journal of the American College of Cardiology, 2019, 73, 2123-2132.	1.2	94
28	Impact of Watchman and Amplatzer Devices on Left Atrial Appendage AdjacentÂStructures and Healing ResponseÂin a Canine Model. JACC: Cardiovascular Interventions, 2014, 7, 801-809.	1.1	92
29	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. American Heart Journal, 2018, 205, 1-11.	1.2	84
30	3-Year Outcomes of the Edwards SAPIEN Transcatheter Heart Valve forÂConduit Failure in the Pulmonary Position From the COMPASSION Multicenter Clinical Trial. JACC: Cardiovascular Interventions, 2018, 11, 1920-1929.	1.1	82
31	1-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC: Cardiovascular Interventions, 2020, 13, 2344-2357.	1.1	68
32	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure. Circulation, 2021, 144, 426-437.	1.6	68
33	Impact of Tricuspid Regurgitation on Clinical Outcomes. Journal of the American College of Cardiology, 2020, 76, 1305-1314.	1.2	63
34	Propensity-Matched Comparison of OralÂAnticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN. JACC: Cardiovascular Interventions, 2019, 12, 1055-1063.	1.1	55
35	Novel Multiphase Assessment for Predicting Left Ventricular Outflow Tract Obstruction Before Transcatheter MitralÂValve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2402-2412.	1.1	49
36	Impact of Pulmonary Hypertension on Outcomes in Patients With Functional Mitral Regurgitation Undergoing Percutaneous Edge-to-Edge Repair. American Journal of Cardiology, 2014, 114, 1735-1739.	0.7	48

#	Article	IF	Citations
37	Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients. Heart, 2019, 105, 1622-1628.	1.2	46
38	Evaluation of Renal Function Before and After Percutaneous Mitral Valve Repair. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	44
39	Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses. JACC: Cardiovascular Interventions, 2021, 14, 859-872.	1.1	44
40	2-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC: Cardiovascular Interventions, 2021, 14, 1538-1548.	1.1	40
41	Cardiovascular Therapies Targeting LeftÂAtrial Appendage. Journal of the American College of Cardiology, 2018, 72, 448-463.	1.2	39
42	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010300.	1.4	39
43	Incidence, Characteristics, and Clinical Course of Device-Related Thrombus AfterÂWatchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients. JACC: Clinical Electrophysiology, 2017, 3, 1380-1386.	1.3	38
44	The Evolution of Percutaneous MitralÂValveÂRepair Therapy. Journal of the American College of Cardiology, 2014, 64, 2688-2700.	1.2	37
45	latrogenic Atrial Septal Defect After Percutaneous Mitral Valve Repair With the MitraClip System. American Journal of Cardiology, 2018, 121, 475-479.	0.7	37
46	Postprocedural Changes of Tricuspid Regurgitation After MitraClip Therapy for Mitral Regurgitation. American Journal of Cardiology, 2017, 120, 857-861.	0.7	34
47	Predictors of Clinical Response to Transcatheter Reduction of SecondaryÂMitral Regurgitation. Journal of the American College of Cardiology, 2020, 76, 1007-1014.	1.2	34
48	Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. European Journal of Heart Failure, 2012, 14, 939-945.	2.9	33
49	NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in HeartÂFailure. JACC: Cardiovascular Interventions, 2020, 13, 2317-2328.	1.1	33
50	Prospective Evaluation of TMVR for Failed Surgical Annuloplasty Rings. JACC: Cardiovascular Interventions, 2021, 14, 846-858.	1.1	33
51	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 879-889.	1.1	32
52	Balloon Mitral Valvuloplasty in the United States: A 13-Year Perspective. American Journal of Medicine, 2014, 127, 1126.e1-1126.e12.	0.6	28
53	Pulmonary Hypertension in TranscatheterÂMitral Valve Repair for Secondary Mitral Regurgitation. Journal of the American College of Cardiology, 2020, 76, 2595-2606.	1.2	27
54	Prognostic Value of Increased Mitral Valve Gradient After Transcatheter Edge-to-Edge Repair for Primary MitralÂRegurgitation. JACC: Cardiovascular Interventions, 2022, 15, 935-945.	1.1	25

#	Article	IF	CITATIONS
55	Speckle-Tracking Echocardiographic Measures of Right Ventricular Function Correlate With Improvement in Exercise Function After Percutaneous Pulmonary Valve Implantation. Journal of the American Society of Echocardiography, 2015, 28, 1036-1044.	1.2	24
56	Health Status Changes and Outcomes inÂPatients With HeartÂFailure and MitralÂRegurgitation. Journal of the American College of Cardiology, 2020, 75, 2099-2106.	1.2	24
57	Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). Journal of Interventional Cardiology, 2019, 2019, 1-8.	0.5	22
58	Transcatheter Procedure for ResidualÂMitral Regurgitation After MitraClip Implantation Using AmplatzerÂDuct Occluder II. JACC: Cardiovascular Interventions, 2016, 9, 1280-1288.	1.1	21
59	Usefulness of Intraprocedural Pulmonary Venous Flow for Predicting Recurrent Mitral Regurgitation and Clinical Outcomes After Percutaneous Mitral Valve Repair With the MitraClip. JACC: Cardiovascular Interventions, 2019, 12, 140-150.	1.1	21
60	Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy. Circulation: Heart Failure, 2020, 13, e007293.	1.6	20
61	Different indicators for postprocedural mitral stenosis caused by single- or multiple-clip implantation after percutaneous mitral valve repair. Journal of Cardiology, 2018, 71, 336-345.	0.8	19
62	Mechanisms of mitral regurgitation after percutaneous mitral valve repair with the MitraClip. European Heart Journal Cardiovascular Imaging, 2020, 21, 1131-1143.	0.5	18
63	Impact of Percutaneous Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation. Circulation Journal, 2021, 85, 1001-1010.	0.7	18
64	Meta-Analysis Comparing WatchmanTM and Amplatzer Devices for Stroke Prevention in Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2020, 7, 89.	1.1	17
65	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in HeartÂFailure With Secondary MitralÂRegurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2331-2341.	1.1	16
66	Impact of Forward Stroke Volume Response on Clinical and Structural Outcomes After Percutaneous Mitral Valve Repair With MitraClip. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	15
67	Direct Current Cardioversion of AtrialÂFibrillation in Patients With LeftÂAtrial Appendage Occlusion Devices. Journal of the American College of Cardiology, 2019, 74, 2267-2274.	1.2	15
68	Diastolic dysfunction measured by cardiac magnetic resonance imaging in women with signs and symptoms of ischemia but no obstructive coronary artery disease. International Journal of Cardiology, 2016, 220, 775-780.	0.8	14
69	Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2795-2803.	1.1	14
70	Right-to-Left Shunt Through latrogenic Atrial Septal Defect After MitraClip Procedure. JACC: Cardiovascular Interventions, 2020, 13, 1544-1553.	1.1	14
71	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. Journal of the American Society of Echocardiography, 2021, 34, 955-965.	1.2	14
72	Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. European Heart Journal, 2022, 43, 1639-1648.	1.0	14

#	Article	IF	CITATIONS
73	Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. Circulation: Cardiovascular Interventions, 2022, 15, .	1.4	14
74	Transseptal Closure of Left Ventricular Pseudoaneurysm Post-Transapical Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2014, 7, e177-e178.	1.1	13
75	Left atrial pressure is associated with iatrogenic atrial septal defect after mitral valve clip. Heart, 2019, 105, 864-872.	1.2	12
76	Impact of Pre-existing Kidney Dysfunction on Outcomes Following Transcatheter Aortic Valve Replacement. Current Cardiology Reviews, 2017, 13, 283-292.	0.6	12
77	Comparison of mitral valve geometrical effect of percutaneous edge-to-edge repair between central and eccentric functional mitral regurgitation: clinical implications. European Heart Journal Cardiovascular Imaging, 2019, 20, 455-466.	0.5	11
78	Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). International Journal of Cardiology, 2014, 172, e114-e115.	0.8	9
79	Current Assessment of Mitral Regurgitation. Journal of the American College of Cardiology, 2015, 65, 1089-1091.	1.2	8
80	First experience of the usage of a <scp>GORE</scp> <scp>CARDIOFORM</scp> <scp>S</scp> eptal <scp>O</scp> ccluder device for treatment of a significant residual commissural mitral regurgitation jet following a <scp>M</scp> itra <scp>C</scp> lip procedure. Catheterization and Cardiovascular Interventions, 2018, 92, 607-610.	0.7	8
81	Longâ€term transesophageal echocardiography after patent foramen ovale closure by BioSTAR and Amplatzer patent foramen ovale occluders. Catheterization and Cardiovascular Interventions, 2020, 95, 349-354.	0.7	8
82	Left atrial appendage size in patients with atrial fibrillation in Japan and the United States. Heart and Vessels, 2021, 36, 277-284.	0.5	8
83	Left atrial appendage closure in patients with prohibitive anatomy: Insights from PINNACLE FLX. Heart Rhythm, 2021, 18, 1153-1161.	0.3	8
84	Age-Related Outcomes After Transcatheter Mitral Valve Repair in Patients With HeartÂFailure. JACC: Cardiovascular Interventions, 2022, 15, 397-407.	1.1	8
85	Percutaneous Transcatheter Mitral Valve Repair. Journal of the American College of Cardiology, 2013, 62, 1062-1064.	1.2	7
86	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in HeartÂFailure. JACC: Heart Failure, 2021, 9, 559-567.	1.9	6
87	In-tunnel closure of patent foramen ovale with a FlatStent EFTM. Kardiologia Polska, 2015, 73, 549-556.	0.3	5
88	Relation Between Pulmonary Venous Flow and Left Atrial Pressure During Percutaneous Mitral Valve Repair With the MitraClip. American Journal of Cardiology, 2018, 122, 1379-1386.	0.7	4
89	Device- and LAA-Specific Characteristics for Successful LAA Closure. Interventional Cardiology Clinics, 2014, 3, 239-254.	0.2	3
90	Mitral annular motion in patients after transcatheter MitraClip and mitral valve surgery. Echocardiography, 2017, 34, 334-339.	0.3	2

#	Article	IF	CITATIONS
91	Utilization of 3 amplatzer occluders for closure of post-myocardial infarction ventricular septal defect. Journal of Invasive Cardiology, 2012, 24, E101-3.	0.4	2
92	Transcatheter Occlusion of the Left Atrial Appendage. Interventional Cardiology Clinics, 2013, 2, 225-234.	0.2	1
93	Patching residual leaks following a MitraClip procedure. EuroIntervention, 2019, 15, e482-e483.	1.4	1
94	Opening and Closing in Tandem. JACC: Cardiovascular Interventions, 2016, 9, 1496-1498.	1.1	0
95	Left Atrial Appendage: What Do We Know? What Do We Need? Where Are We Going?. Cardiac Electrophysiology Clinics, 2020, 12, xv.	0.7	0
96	Left ventricular outflow tract area after percutaneous transseptal transcatheter mitral valve implantation: A threeâ€dimensional transesophageal echocardiography study. Echocardiography, 2021, 38, 932-942.	0.3	0
97	Percutaneous edge-to-edge mitral valve repair for symptomatic high surgical risk patients with significant mitral regurgitation – Short term and one year follow up results from a single center in India. Indian Heart Journal, 2021, 73, 497-498.	0.2	0
98	Mitral valve repair in an octogenarian with symptomatic severe mitral regurgitation: First use of MitraClip in India. The National Medical Journal of India, 2020, 33, 207.	0.1	0
99	Letter by Natale et al Regarding Article, "Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial― Circulation, 2022, 145, e847-e848.	1.6	0
100	Letter by Price et al Regarding the Article, "Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial― Circulation, 2022, 145, e849.	1.6	0